Introduction: Increasingly, identification of BRAF mutation in colorectal cancer is used to guide management and predict cancer behaviour. There is, however, still significant diversity within this cohort of patients, both in terms of clinical phenotype and treatment outcomes. This may be explained, at least in part, by differences between classes of BRAF mutations and the presence of concomitant mutations.
Methods: We present a retrospective cohort study of sequential patients diagnosed with BRAF-mutated (V600 and non-V600) colorectal cancer between 2014 and 2022. Information regarding presentation, treatment outcomes and molecular subtype was identified using the electronic medical record.
Results: This study included 406 patients with BRAF-mutated colorectal cancer, 253 (228
V600BRAF) of whom had localised disease and 153 (137
V600BRAF) with metastatic disease at the time of diagnosis. In patients with localised disease at diagnosis, the
V600BRAF mutation was associated with older median age (73 vs. 63 years,
p = 0.04) and a higher prevalence of right-sided primary (73% vs. 40%,
p < 0.01), mismatch repair deficiency (56% vs. 8%,
p < 0.01), and faster time to disease relapse (
p = 0.006). In the metastatic setting,
non-V600BRAF mutation was associated with a higher prevalence of KRAS mutation (27% vs. 1%,
p < 0.01), NRAS mutation (14% vs. 3%,
p = 0.04) and PIK3CA mutation (33% vs. 8%,
p = 0.02). Mismatch repair deficiency was more common in patients with
V600BRAF mutations than in those with
non-V600BRAF mutations (20% vs. 0%,
p = 0.01). The median survival of patients with the
V600BRAF mutation was 14 months, and 34 months in those with
non-V600BRAF mutations. Concomitant RNF43 mutation in metastatic disease, was associated with a significantly higher incidence of disease control from combined BRAF and EGFR inhibition, when compared to those without an RNF43 mutation (100% vs. 54%,
p = 0.02).
Conclusions: Presentation and outcomes of BRAF-mutated colorectal cancer are heterogenous. The type of BRAF mutation, and the presence of concomitant RNF43 mutation, may explain some of the differences in cancer behaviour. Routine reporting of RNF43 mutations would assist clinicians to give more personalised treatment recommendations.
Full article
